BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
6.93
+0.30 (4.52%)
At close: Oct 20, 2025, 4:00 PM EDT
6.90
-0.03 (-0.42%)
After-hours: Oct 20, 2025, 7:50 PM EDT
BioCryst Pharmaceuticals Revenue
BioCryst Pharmaceuticals had revenue of $163.35M in the quarter ending June 30, 2025, with 49.41% growth. This brings the company's revenue in the last twelve months to $557.51M, up 45.85% year-over-year. In the year 2024, BioCryst Pharmaceuticals had annual revenue of $450.71M with 36.00% growth.
Revenue (ttm)
$557.51M
Revenue Growth
+45.85%
P/S Ratio
2.48
Revenue / Employee
$961,217
Employees
580
Market Cap
1.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 450.71M | 119.30M | 36.00% |
Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BCRX News
- 14 hours ago - BioCryst to Report Third Quarter 2025 Financial Results on November 3 - GlobeNewsWire
- 3 days ago - Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS - Business Wire
- 6 days ago - BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript - Seeking Alpha
- 6 days ago - BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga
- 6 days ago - BioCryst to buy Astria Therapeutics in $700 million deal - Reuters
- 6 days ago - BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - Business Wire
- 17 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business - GlobeNewsWire